Article info
PDFTherapeutics
Randomised controlled trial
Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine
- Correspondence to: Pierre N Tariot
Banner Alzheimer's Institute, 901 E Willetta ST, Phoenix, Arizona 85006, USA; Pierre.tariot{at}bannerhealth.com
Citation
Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine
Publication history
- First published June 26, 2012.
Online issue publication
July 20, 2019
Article Versions
- Previous version (20 July 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions